{"id":"W2425644022","doi":"10.1056/nejmoa1603827","title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","year":2016,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7350,"is_retracted":false,"has_abstract":true,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"National Center for Advancing Translational Sciences; Relypsa; National Institutes of Health; ResMed; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Orexigen Therapeutics; Massachusetts Medical Society; Novo Nordisk; Intarcia Therapeutics; Sanofi; Esperion Therapeutics; GlaxoSmithKline; Amgen; Pfizer; Celgene","keywords":"Liraglutide; Type 2 diabetes; Medicine; Internal medicine; Diabetes mellitus; Cardiology; Endocrinology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}